This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
These 5 Companies are Earnings Perfection
by Tracey Ryniec
Looking for only the best this earnings season? These companies haven't missed on earnings in the last 5 years.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $69.13, moving +1.5% from the previous trading session.
The Zacks Analyst Blog Highlights: Merck, Abbott, Lockheed Martin, United Parcel Service and Bank of New York Mellon
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Merck, Abbott, Lockheed Martin, United Parcel Service and Bank of New York Mellon
Top Analyst Reports for Merck, Abbott & Lockheed Martin
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Merck (MRK), Abbott (ABT) and Lockheed Martin (LMT).
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $70.63, marking a +1.45% move from the previous day.
Why Abbott (ABT) Could Beat Earnings Estimates Again
by Zacks Equity Research
Abbott (ABT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $70.08 in the latest trading session, marking a +0.47% move from the prior day.
5 Beaten-Down Medical Product Stocks to Rebound in 2019
by Nabaparna Bhattacharya
As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $72.53, moving +0.96% from the previous trading session.
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $74.05 in the latest trading session, marking a +1.08% move from the prior day.
Abbott (ABT) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $68.53 in the latest trading session, marking a -0.77% move from the prior day.
Abbott (ABT) Up 3.8% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Abbott (ABT) Stock Moves -0.12%: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $69.41 in the latest trading session, marking a -0.12% move from the prior day.
Surmodics' (SRDX) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Surmodics (SRDX) sees solid segmental performance in fiscal Q4; gains from alliance with Abbott.
Abbott (ABT) Gains As Market Dips: What You Should Know
by Zacks Equity Research
In the latest trading session, Abbott (ABT) closed at $72.96, marking a +0.63% move from the previous day.
Abbott (ABT) Q3 Earnings Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 1.35% and -0.12%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed the most recent trading day at $69.30, moving +1.91% from the previous trading session.
Abbott (ABT) Gains But Lags Market: What You Should Know
by Zacks Equity Research
Abbott (ABT) closed at $67.68 in the latest trading session, marking a +1.11% move from the prior day.
DexCom Launches CLARITY Mobile App, Strengthens CGM Profile
by Zacks Equity Research
DexCom (DXCM) benefits from the diabetes care space as it adopts cloud-based services for Continuous Glucose Monitoring.
Abbott (ABT) Q3 Earnings Top Estimates, Guidance Narrowed
by Zacks Equity Research
Within Structural Heart, growth was driven by several product areas across Abbott's (ABT) broad portfolio, including AMPLATZER PFO Occluder and MitraClip.
Bank Stocks Earnings Scorecard, Fed Minutes, & Trade Talks on "Hiatus"
by Ryan McQueeney
Ryan McQueeney discusses the upcoming Fed minutes and Wilbur Ross' comments about U.S.-China trade talks. He also recaps earnings reports from United, Abbot Labs, and U.S. Bancorp. Later, he takes at a look at the earnings scorecard for bank stocks.
Earnings & Economic Data Deluge
by Zacks Equity Research
Earnings & Economic Data Deluge
Q3 Earnings Stay (Mostly) Strong, Plus Housing Data
by Mark Vickery
With new Housing Starts, Building Permits and Mortgage Application data, we continue to collect new Q3 earnings results, particularly from UAL, ABT and USB.
Abbott (ABT) Q3 Earnings Top Estimates
by Zacks Equity Research
Abbott (ABT) delivered earnings and revenue surprises of 1.35% and -0.12%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
5 Earnings Charts in the Spotlight
by Tracey Ryniec
Want to know what's going on in the global economy? Check in with these five companies reporting earnings this week.